Business Wire

The Australian and New Zealand College of Anaesthetists Joins the Patient Safety Movement Foundation as a Committed Partner to Eliminate Preventable Harm in Hospitals

Jaa

The Australian and New Zealand College of Anaesthetists (ANZCA) is partnering with the Patient Safety Movement Foundation (PSMF) in support of the mission to eliminate medical errors within hospitals - the 14 th leading cause of death worldwide. The announcement was made publicly at ANZCA’s Annual Scientific Meeting (ASM) in Sydney on May 8, 2018. Dr. Michael A. E. Ramsay, Anaesthetist, and Patient Safety Movement Foundation Board Member was present to sign the Commitment to Action Letter publicly alongside ANZCA President, Professor David A. Scott.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180509005874/en/

Dr. Michael A. E. Ramsay, Patient Safety Movement Board Member, (left) and ANZCA President, Professo ...

Dr. Michael A. E. Ramsay, Patient Safety Movement Board Member, (left) and ANZCA President, Professor David A. Scott (right), sign ANZCA’s Commitment to Action Letter (Photo: Business Wire)

“We are thrilled to have the Australian and New Zealand College of Anaesthetists join us in our fight to eliminate preventable harm from hospitals. Through this partnership, we will reach the next generation of anaesthetists and recruit two important countries in our global effort to improve patient safety through the implementation of evidence-based processes,” explains Joe Kiani, Founder and Chairman of the Patient Safety Movement Foundation.

ANZCA runs one of Australasia’s largest specialist medical colleges and is the professional organisation representing nearly 6400 specialist anaesthetists and 1500 anaesthetists in training. ANZCA’s commitment represents the first by a major partner in Australia or New Zealand and joins 4,598 other committed hospitals and partners in 44 countries working towards the goal of eliminating preventable harm in hospitals.

“Patient harm and patient deaths occur in our hospitals daily, despite our best intentions. Many of these events are preventable if we apply existing knowledge, especially with the aid of new technologies. ANZCA welcomes this partnership which recognises our joint commitment to safety and quality in our specialty and improving patient safety,” said Professor Scott. “Initiatives such as this are so important for patients, hospitals and the specialty of anaesthesia.”

As a Committed Partner, ANZCA will work with the PSMF to improve patient outcomes with an acute focus on anesthesiology and perioperative care. Actions include:

    a.   Spreading the PSMF mission to ANZCA members;
 
b. Identifying Actionable Patient Safety Solutions (APSS) that align with ANZCA’s standards and/or policies and inviting members working in hospitals to implement APSS or similar processes with the aim of eliminating preventable patient deaths in hospitals;
 
c. Annually disseminating relevant APSS to ANZCA members;
 
d. Engaging with the PSMF at its annual meetings to develop and improve relevant APSS.
 

To learn more about the Patient Safety Movement Foundation, please visit www.patientsafetymovement.org.

About Patient Safety Movement Foundation: More than 200,000 people die every year in U.S. hospitals and 4.8 million worldwide in ways that could have been prevented. The Patient Safety Movement Foundation is a global non-profit which creates free tools for patients and hospitals. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to ZERO by 2020 (0X2020™). Improving patient safety will require a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The Patient Safety Movement Foundation works with all stakeholders to address the problems with actionable solutions for patient safety. The Foundation also convenes the World Patient Safety, Science & Technology Summit. The Summit brings together some of the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward ZERO preventable deaths by 2020. Visit patientsafetymovement.org.

About ANZCA: The Australian and New Zealand College of Anaesthetists (ANZCA) is the professional organisation for about 6400 specialist anaesthetists (Fellows) and 1500 anaesthetists in training (trainees). One of Australia's largest specialist medical colleges, ANZCA, along with its Faculty of Pain Medicine, is responsible for the training, examination and specialist accreditation of anaesthetists and pain medicine specialists and the standards of clinical practice in Australia and New Zealand. The College also plays a significant role in the advancement of anaesthesia in southeast Asia and South Pacific island countries.

Contact information

Patient Safety Movement Foundation
Tanya Lyon, Public Relations Manager
(949) 351-2858
tanya.lyon@patientsafetymovement.org
or
Australian & New Zealand College of Anaesthetists
Carolyn Jones, Media Manager
+61 3 8517 5303
cjones@anzca.edu.au

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)22.9.2018 01:13Tiedote

Glorious beaches by day and theme park fireworks by night just got more convenient for Philadelphia travelers. American Airlines announced today that it will begin nonstop flights to Orlando Melbourne International Airport (MLB) starting February 16, 2019. The Central Florida airport is conveniently located in the heart of the tourism region and is the closest airport to NASA rocket launches, Port Canaveral’s cruises and what critics call “some of the most beautiful beaches Florida has to offer.” The flights will depart Saturdays from Philadelphia at 8:05 a.m., arriving in Florida at 10:48 a.m. The Embraer 175 jet arrival time syncs perfectly with cruise ship noon early boarding. Melbourne Airport Express offers nonstop shuttle service to the port, and all major rental car companies are onsite. The return flight to PHL departs at 11:24 a.m. and arrives in PHL at 1:55 p.m., with enough time to connect to some of American’s largest international destinations, including recently announced

Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice21.9.2018 20:43Tiedote

BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Amy Palladino has joined the agency as Executive Vice President, Managing Director in the agency’s U.S. Corporate Practice. Based in New York, Palladino will focus on senior client counsel and executive positioning for the agency’s largest corporate clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005507/en/ Amy Palladino Joins BCW (Burson Cohn & Wolfe) “Amy is a talented and highly experienced communications executive with a track record of solving clients’ complex challenges and building business through smart, integrated communications approaches,” said Chris Foster, President, North America, BCW. “Her creativity and judgement will be enormously valuable to our current and prospective clients.” Palladino has more than 20 years of experience advising global clients across numerous industries, including technology, healthcar

Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 19:41Tiedote

Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo

Florian Winterstein Becomes New CEO of Jedox21.9.2018 18:46Tiedote

The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it

Avinor to Test Autonomous Snowploughs at Oslo Airport This Winter21.9.2018 17:37Tiedote

Since 2010 Avinor has had a vision and a desire to automate winter maintenance. In March autonomous snow clearing was demonstrated at Fagernes Airport, and this winter Avinor is taking this a step further by testing two autonomous snowploughs at Oslo Airport. The project is one of the first globally where large machinery will operate autonomously to keep snow away from airport areas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005363/en/ Avinor to Test Autonomous Snowploughs at Oslo Airport This Winter (Photo: Business Wire) “Innovation is important to Avinor. In the future, many tasks in aviation will be resolved in other ways than today. Avinor wants to test autonomy, and does of course see a potential for rationalization in the future through new solutions for winter operations and in other areas. Avinor is at the forefront of testing this technology, but it is essential that safety is ensured in all such testing

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 16:30Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme